Livforsakringsbolaget Skandia Omsesidigt Buys 54,700 Shares of Cencora, Inc. $COR

Livforsakringsbolaget Skandia Omsesidigt grew its stake in Cencora, Inc. (NYSE:COR) by 2,917.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 56,575 shares of the company’s stock after buying an additional 54,700 shares during the period. Cencora makes up about 0.7% of Livforsakringsbolaget Skandia Omsesidigt’s holdings, making the stock its 26th biggest holding. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Cencora were worth $17,676,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Norges Bank purchased a new position in Cencora in the second quarter worth $695,215,000. Marshall Wace LLP increased its stake in Cencora by 518.9% in the third quarter. Marshall Wace LLP now owns 1,995,118 shares of the company’s stock valued at $623,534,000 after acquiring an additional 1,672,762 shares during the last quarter. Mizuho Markets Americas LLC raised its position in Cencora by 116.4% during the third quarter. Mizuho Markets Americas LLC now owns 212,800 shares of the company’s stock valued at $66,506,000 after purchasing an additional 1,511,906 shares in the last quarter. Artisan Partners Limited Partnership purchased a new stake in Cencora during the second quarter valued at about $411,888,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Cencora by 528.9% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,475,859 shares of the company’s stock worth $461,250,000 after purchasing an additional 1,241,186 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Weiss Ratings upgraded Cencora from a “hold (c+)” rating to a “buy (b)” rating in a report on Thursday, February 5th. JPMorgan Chase & Co. raised their price objective on Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a report on Tuesday, February 10th. Wall Street Zen lowered Cencora from a “buy” rating to a “hold” rating in a research note on Friday, November 28th. Leerink Partners reiterated an “outperform” rating on shares of Cencora in a research report on Tuesday. Finally, Barclays increased their price target on shares of Cencora from $400.00 to $425.00 and gave the company an “overweight” rating in a research report on Friday, February 13th. Twelve equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, Cencora currently has a consensus rating of “Moderate Buy” and an average price target of $403.17.

Cencora Stock Down 3.2%

Shares of NYSE:COR opened at $334.69 on Wednesday. The stock’s 50-day moving average price is $355.45 and its 200-day moving average price is $339.50. Cencora, Inc. has a 12-month low of $260.23 and a 12-month high of $377.54. The stock has a market capitalization of $65.11 billion, a P/E ratio of 40.23, a price-to-earnings-growth ratio of 1.61 and a beta of 0.68. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62.

Cencora (NYSE:COR) last released its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, beating analysts’ consensus estimates of $4.04 by $0.04. The company had revenue of $85.93 billion during the quarter, compared to analyst estimates of $86.12 billion. Cencora had a return on equity of 176.54% and a net margin of 0.50%.Cencora’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.73 EPS. On average, equities analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Shareholders of record on Friday, February 13th were given a $0.60 dividend. The ex-dividend date was Friday, February 13th. This represents a $2.40 annualized dividend and a yield of 0.7%. Cencora’s payout ratio is presently 28.85%.

Insider Activity

In other news, CEO Robert P. Mauch sold 5,096 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total value of $1,807,704.08. Following the transaction, the chief executive officer owned 66,726 shares in the company, valued at approximately $23,669,713.98. This trade represents a 7.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Elizabeth S. Campbell sold 3,351 shares of Cencora stock in a transaction on Friday, December 19th. The stock was sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the completion of the transaction, the executive vice president directly owned 23,891 shares in the company, valued at approximately $8,173,111.10. The trade was a 12.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 15,220 shares of company stock valued at $5,282,867. 0.38% of the stock is currently owned by company insiders.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.